Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

UPDATE: Cidara Therapeutics Q3 Adj. EPS $(1.43) Misses $(1.35) Estimate

Author: Benzinga Newsdesk | November 06, 2025 05:55pm
Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(1.43) per share which missed the analyst consensus estimate of $(1.35) by 6.24 percent. This is a 39.92 percent increase over losses of $(2.38) per share from the same period last year.

Posted In: CDTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist